News & Analysis as of

Biotechnology France

Dechert LLP

Overview of financing options for French biotech companies

Dechert LLP on

The trajectory of a biotech company is often full of ups and downs, influenced by unpredictable changes in market conditions. It is therefore imperative for biotech companies to be agile in finding the most appropriate...more

Hogan Lovells

French decree regarding the “direct access”: a half-hearted step forward for pharmaceutical innovations

Hogan Lovells on

Publication of the French decree regarding the experimentation of the "direct access" to pharmaceutical products with anticipated reimbursement: a half-hearted step forward for pharmaceutical innovations....more

Hogan Lovells

Décret relatif à l’accès direct : une avancée en demi-teinte pour les innovations pharmaceutiques

Hogan Lovells on

Publication du décret relatif à l’expérimentation du dispositif d’accès direct des médicaments à un financement anticipé : une avancée en demi-teinte s’agissant de l’accès au marché des innovations pharmaceutiques en France....more

Latham & Watkins LLP

Life Sciences Law Review - 11th Edition, France Chapter

Latham & Watkins LLP on

The eleventh edition of The Life Sciences Law Review covers a total of 24 jurisdictions, providing an overview of legal requirements of interest to pharmaceutical, biotechnology and medical device companies. The chapters are...more

Hogan Lovells

JPM2023 Trendspotting: successful early access in the EU

Hogan Lovells on

As the industry readies itself for the January 2023 pilgrimage to the J.P. Morgan Healthcare Conference (JPM) and Biotech Showcase in San Francisco, our market-leading life sciences and health care industry team has prepared...more

McDermott Will & Emery

Intellectual Property & Health | News To Know – June 2022

McDermott Will & Emery on

RUSSIA RESPONDS TO WESTERN SANCTIONS WITH PATENT RETALIATION - On March 6, 2022, the Russian government retaliated against the West’s imposition of sanctions by issuing a decree permitting patented innovations to be used...more

Hogan Lovells

Médicaments hybrides et inscription au répertoire des groupes génériques

Hogan Lovells on

Le Conseil d’Etat confirme que seule la décision d’autorisation de mise sur le marché peut définir un médicament en tant que générique. Par deux décisions récentes du 7 juillet 2021 (Johnson & Johnson, req. n° 437803 et...more

Hogan Lovells

Hybrid products and registration in the generics register ("répertoire des groupes génériques")

Hogan Lovells on

The French supreme administrative Court ("Conseil d'Etat") confirms that only the marketing authorisation may define a pharmaceutical product as generic. In two recent decisions of 7 July 2021 (Johnson & Johnson, req. no....more

Dechert LLP

UK Life Sciences and Healthcare Newsletter: Life Sciences: What's new in France? Avastin/Lucentis case: French Competition...

Dechert LLP on

On 9 September 2020, the French Competition Authority (“FCA”) issued an infringement decision sanctioning Novartis and Roche with record fines for the pharmaceutical sector in France, totaling 444 million euros, for having...more

White & Case LLP

New expansion of foreign direct investments control regime in France and the impact on French biotech companies

White & Case LLP on

White & Case Technology Newsflash - In line with the increased protectionism around foreign direct investments (FDI) in the past few years, the economic impact of COVID-19 led to a worldwide rapid expansion of existing...more

Cohen & Gresser LLP

COVID-19 and Foreign Investments in France: Strengthening of the Control

Cohen & Gresser LLP on

In the context of the COVID-19 crisis, the French government introduced some new rules to strengthen France's control over foreign investments: •through a Decree (décret) and an Order (arrêté) dated 22 July 2020, the...more

Dechert LLP

Increased regulatory scrutiny of foreign direct investments in the healthcare sector

Dechert LLP on

Key Takeaways - - Foreign Direct Investment (FDI) controls are proliferating around the globe. Since the pandemic, “health” has become a particular focus.  - Several countries have adapted their existing FDI rules, or...more

Morgan Lewis

COVID-19: Control of Foreign Direct Investments in France

Morgan Lewis on

Evidence is growing of a hardening of French public policy regarding the need for political control of acquisitions of French companies and other foreign direct investment (FDI) transactions. In part this is prompted by a...more

White & Case LLP

COVID-19: Following the paths of Spain, and soon Germany, the French Government Further Strengthens Foreign Investments Control

White & Case LLP on

The French Foreign Investments Control regime has recently been reinforced following a reform introduced by Decree n° 2019-1590 of 31 December 2019 and the Ministerial Order of 31 December 2019 relating to foreign investments...more

Skadden, Arps, Slate, Meagher & Flom LLP

France Moves To Protect Strategic Assets Amid COVID-19 Pandemic

On April 29, 2020, the French Minister of the Economy (the Minister) announced that French foreign investment rules will be adopted with the policy goal of protecting French strategic assets in the context of the COVID-19...more

Hogan Lovells

View from the Horizon: Pricing and financial regulation of health products in France

Hogan Lovells on

On June 27 the third edition of our new global series, Life Sciences and Health Care Horizons, took place in Paris with discussions focused on the pricing and financial regulation of health products after the latest reforms....more

Orrick - Antitrust Watch

Dusting the Regulatory Framework – French Competition Authority Seeks to Liberalize Distribution of Drugs and Private Medical...

On April 4, 2019, just three months after the publication of the European Commission (EC) report on “Competition enforcement in the pharmaceutical sector,” the French Competition Authority (FrCA) issued its report n°19-A-08...more

Hogan Lovells

Relocation of the European Medicines Agency – France shows EMA its smooth moves

Hogan Lovells on

With Brexit under way, the European Medicines Agency is looking for a new home. France revealed itself as a serious contender when it considered offering not just one hosting place for the Agency, but five! Up until recently,...more

WilmerHale

In Case You Missed It: Launch Links - February 2016 #4

WilmerHale on

Some interesting links we found across the web this week: Has this year's startup funding slowdown been overblown? Debate continues over the perceived downturn in the market for venture capital, as a new...more

19 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide